J&J re­ceives fifth FDA nod for treat­ing mul­ti­ple myelo­ma, with boxed warn­ing and REMS in tow

John­son & John­son’s Janssen has re­ceived its fifth drug ap­proval for mul­ti­ple myelo­ma, se­cur­ing an ac­cel­er­at­ed nod for its bis­pe­cif­ic Talvey on Thurs­day morn­ing. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER